Table 3.
HLA antibodies in B-cell supernatants of donor RO
| Polymorphic antibodies | Antigenic specific antibodies | Panreactive antibodies | ||||||
|---|---|---|---|---|---|---|---|---|
| Expt. | Interval† | Frequency (× 106) | GOF‡ | HLA–specificity | Frequency (× 106) | GOF‡ | Frequency (× 106) | GOF‡ |
| 1 | 14 | 222 | 24·5* | A2 | 95 | 7·7 | 167 | 60·5* |
| A2/A28 | 41 | 16·2* | ||||||
| B60 | 20 | 12·5* | ||||||
| 2 | 14 | 280 | 16·2* | A2 | 119 | 5·4 | 386 | 83·6* |
| A2/A28 | 86 | 10·7 | ||||||
| B60 | 25 | 10·9* | ||||||
| 6 | 20 | 132 | 9·1 | A2 | 33 | 1·9 | 0 | |
| A2/A28 | 26 | 6·3 | ||||||
| B60 | 41 | 6·9 | ||||||
| 7 | 20 | 118 | 2·07 | A2 | 77 | 6·4 | 0 | |
| A2/A28 | 7 | 4·1 | ||||||
| B60 | 14 | 7·1 | ||||||
†
Time in months elapsed since the third pregnancy.
‡
GOF; goodness-of-fit, if value is followed by
*
the frequency value is statistically not significant.